BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35172875)

  • 1. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial.
    Kautz-Freimuth S; Redaèlli M; Shukri A; Kentenich H; Simic D; Mildenberger V; Schmutzler R; Rhiem K; Stock S
    BMC Med Inform Decis Mak; 2023 Oct; 23(1):223. PubMed ID: 37845719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
    Kautz-Freimuth S; Redaèlli M; Rhiem K; Vodermaier A; Krassuski L; Nicolai K; Schnepper M; Kuboth V; Dick J; Vennedey V; Wiedemann R; Schmutzler R; Stock S
    BMC Med Inform Decis Mak; 2021 Jun; 21(1):180. PubMed ID: 34090422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
    BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study.
    Isselhard A; Töpper M; Berger-Höger B; Steckelberg A; Fischer H; Vitinius F; Beifus K; Köberlein-Neu J; Wiedemann R; Rhiem K; Schmutzler R; Stock S
    Trials; 2020 Jun; 21(1):501. PubMed ID: 32513307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    Steenbeek MP; van Bommel MHD; Harmsen MG; Hoogerbrugge N; van Doorn HC; Keurentjes JHM; van Beurden M; Zweemer RP; Gaarenstroom KN; Penders CGJ; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; IntHout J; de Hullu JA; Hermens RPMG
    Gynecol Oncol; 2021 Nov; 163(2):371-377. PubMed ID: 34456057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
    This P; de la Rochefordière A; Savignoni A; Falcou MC; Tardivon A; Thibault F; Alran S; Fourchotte V; Fitoussi A; Couturaud B; Dolbeault S; Salmon RJ; Sigal-Zafrani B; Asselain B; Stoppa-Lyonnet D;
    Fam Cancer; 2012 Sep; 11(3):473-82. PubMed ID: 22711610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
    Sigal BM; Munoz DF; Kurian AW; Plevritis SK
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation.
    Narod SA; Butler R; Bobrowski D; Akbari MR; Curling D; Lunn J; Ho C; Panahi S; Llacuachaqui M; Donenberg T; Hurley J
    Mol Genet Genomic Med; 2018 Mar; 6(2):301-304. PubMed ID: 29266833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
    Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
    Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial on the effect of an online decision aid for young female cancer patients regarding fertility preservation.
    Ehrbar V; Urech C; Rochlitz C; Zanetti Dällenbach R; Moffat R; Stiller R; Germeyer A; Nawroth F; Dangel A; Findeklee S; Tschudin S
    Hum Reprod; 2019 Sep; 34(9):1726-1734. PubMed ID: 31398258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
    Lynce F; Schlam I; Geng X; Peshkin BN; Friedman S; Dutil J; Nahleh Z; Campos C; Ricker C; Rodriguez P; Denduluri N; Ahn J; Isaacs C; Graves KD
    J Genet Couns; 2021 Apr; 30(2):383-393. PubMed ID: 33010199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitating decision-making in women undergoing genetic testing for hereditary breast cancer: BRECONDA randomized controlled trial results.
    Sherman KA; Kilby CJ; Shaw LK; Winch C; Kirk J; Tucker K; Elder E
    Breast; 2017 Dec; 36():79-85. PubMed ID: 29031121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.